Medicine & Life Sciences

1. Peripheral Nervous System Diseases 100%
2. Neuroendocrine Tumors 97%
3. Neoplasms 77%
4. Coronavirus 72%
5. Bortezomib 70%
6. Paclitaxel 69%
7. Cohort Studies 68%
8. Immunotherapy 66%
9. Nucleotides 66%
10. Drug Therapy 58%
11. Small Intestine 52%
12. Exome 50%
13. Lung Neoplasms 48%
14. Survival 48%
15. Polyneuropathies 47%
16. Non-Small Cell Lung Carcinoma 46%
17. Afatinib 44%
18. abiraterone 43%
19. MDV 3100 42%
20. Registries 41%
21. Charcot-Marie-Tooth Disease 39%
22. Anti-Bacterial Agents 37%
23. Breast Neoplasms 36%
24. Mutation 36%
25. Neuronal Outgrowth 33%
26. Diagnosis-Related Groups 33%
27. Mortality 33%
28. Progression-Free Survival 32%
29. Venous Thromboembolism 31%
30. Spinal Ganglia 31%
31. Residual Neoplasm 30%
32. Genes 30%
33. Therapeutics 30%
34. Tumor Cell Line 29%
35. Poisons 29%
36. Multiple Myeloma 28%
37. Immunosuppression 28%
38. Sarcoma 27%
39. Body Mass Index 26%
40. Cisplatin 26%
41. Communicable Diseases 24%
42. Risk Assessment 24%
43. Melanoma 23%
44. Rodentia 23%
45. Retrospective Studies 23%
46. pembrolizumab 23%
47. Prostatic Neoplasms 22%
48. Odds Ratio 21%
49. Meta-Analysis 21%
50. Myocardial Infarction 21%